Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
DNA VACCINE TECHNOLOGY - A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
Enteris Biopharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' Peptide
Enteris BioPharma, Inc. congratulates Cara Therapeutics on the dosing of the first patients in a Phase II trial of an...Catalent's Proprietary Softgel Technology Used to Provide Daily Dosing of Modified-Release Semi-Solid Formulation
Catalent Pharma Solutions recently welcomed the announcement by OPKO Health that the US Food and Drug Administration has accepted for...Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio
Immune Pharmaceuticals Inc. recently announced it has entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company...FORMULATION DEVELOPMENT - Overcoming Early Phase Development Challenges & Optimizing Formulations With a Minimal Amount of API
ABSTRACT Softgel is a proven and effective delivery technology for poorly soluble drugs and can incorporate a wide range of...SPECIAL FEATURE - Outsourcing Formulation & Manufacturing Development: Using Data & Unique Approaches to Solve Solubility Issues, Target Profiles & Customize Products
Contributor Cindy H. Dubin finds that CMOs are embracing development projects in an effort to establish longer-lasting partnerships with their pharma and biotech clients. These contract developers are deploying innovative techniques aimed at improving solubility and fast-tracking products to market.
Confluence Pharmaceuticals Signs Co-Development & Marketing Agreement
Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals AG recently announced they have signed a definitive agreement to co-develop and market Confluence’s lead...Immune Pharmaceuticals to Develop Novel Topical Nanoparticle Formulation
Immune Pharmaceuticals Inc. recently announced it has entered into a binding memorandum of understanding with Yissum, the Technology Transfer Company...Combination Product Technology to Reach $31 Billion; Sector Attracting Massive Developmental Companies
BCC Research reveals in its new report on drug-device combination products, developments in cell-based therapeutics, progenitor cell exploitation, growth factor...EXECUTIVE INTERVIEW - Ascendia Pharmaceuticals: Sophisticated Formulations for Poorly Soluble Drugs
Jingjun (Jim) Huang, PhD, CEO, and Founder of Ascendia, discusses his company’s unique vision and strategy to provide pharmaceutical companies with a contract research partner that can provide technologies in order to efficiently determine which approach is most suitable for a given molecule.
